BlossomHill Therapeutics Current Assets

BlossomHill Therapeutics posts a current assets of $100M as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Current Assets is one piece of BlossomHill Therapeutics's financial statement story. At $100M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BLSM's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BlossomHill Therapeutics's other metric pages and overview cover the third.

Judging BlossomHill Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $100M here, then scan peer and history charts to see if the gap is persistent.